

*Paris and Toulouse, May 21<sup>st</sup>, 2015*

## DOCUMENTS AVAILABLE FOR ANNUAL GENERAL MEETING OF SHAREHOLDERS

GENTICEL (Euronext Paris and Brussels: FR0011790542 - GTCL), a French biotechnology company and leading developer of innovative immunotherapies targeting cancers caused by the human papillomavirus (HPV), today announces that its shareholders can find all documents (in French) concerning the Annual General Meeting (AGM) of shareholders in the “Assemblée générale” section under the “informations financières” tab of Genticel’s investor website at: [www.genticel-bourse.com](http://www.genticel-bourse.com). As a reminder, the AGM will be held on June 11<sup>th</sup>, 2015 beginning at 10:00 AM at the company’s offices - 5, rue Tronchet, 75008 Paris.

These documents, as required by Article R.225-83 of the French Commercial Code, will also be made available to shareholders at the company’s headquarters: Prologue Biotech, 516, rue Pierre et Marie Curie, 31670 Labège.

A public notice for the AGM, with an agenda and draft resolutions, was published on May 6<sup>th</sup>, 2015 in the “BALO” (*Bulletin des Annonces légales obligatoires*), France’s public notice journal, number 54.

### About Genticel

#### *Aiming to solve a major public health issue.*

Among the 300 million women around the world currently infected with HPV, 500,000 new cases of cervical cancer are identified each year and 275,000 women succumb to the disease. 70% of cervical cancer cases are caused by 2 HPV types and Genticel aims to eliminate them at an early stage with GTL001 (known in Europe as **ProCervix**), its first-in-class immunotherapeutic vaccine candidate. The Company has already completed patient recruitment for **ProCervix**’s phase 2 clinical trial.

#### *Offering a promising technological platform.*

Genticel’s versatile platform, **Vaxiclase**, is ideally suited for the development of immunotherapies against multiple infectious or cancerous diseases. Genticel’s second immunotherapeutic vaccine candidate, **Multivalent HPV**, targets the six most pertinent HPV types in terms of global epidemiology and was designed using the **Vaxiclase** platform. It is currently in preclinical development.

#### *Focusing on value creation.*

**ProCervix** and **Multivalent HPV** could generate, respectively, over €1 billion and €2 billion per year in revenues. Genticel seeks to establish partnerships for these two immunotherapeutic products as of 2016/2017. The versatility of its technological platform, **Vaxiclase**, has generated significant interest in the pharmaceutical industry, as illustrated by the partnership agreement signed in 2015 with the Serum Institute of India Ltd. (SII), the world’s largest producer of vaccines. This partnership is expected to generate \$57 million in revenues for Genticel, before royalties on sales. It will enable SII to develop acellular multivalent combination vaccines against a variety of conditions, notably whooping cough.

For more information, visit [www.genticel.com](http://www.genticel.com)



GENTICEL CONTACT	USA INVESTOR CONTACT	INVESTOR CONTACT	PRESS CONTACT
Valerie Leroy Investor Relations <a href="mailto:investors@genticel.com">investors@genticel.com</a>	Brian Stollar +1 (212) 915 2577 <a href="mailto:bstollar@lifesciadvisors.com">bstollar@lifesciadvisors.com</a>	Corinne Puissant +33 (0)1 53 67 36 77 <a href="mailto:cpuissant@actus.fr">cpuissant@actus.fr</a>	Alexandra Prisa +33 (0)1 53 67 36 90 <a href="mailto:aprisa@actus.fr">aprisa@actus.fr</a>